News | November 13, 2014

Coquí RadioPharmaceuticals Will Build First U.S. Production Facility

The facility will be producing Molybdenum-99, the parent isotope of Technetium-99, the isotope used in 80% of nuclear medicine procedures

 Nov. 13. 2014 — Coquí RadioPharmaceuticals Corp. (Coquí Pharma) is working to become the first commercial producer of lifesaving medical isotopes in the United States.  In 2012, Congress passed legislation making it a national priority to produce Molybdenum-99, an isotope necessary to detect a wide range of diseases, including cardiovascular disease and cancer.

“Among the aspiring medical isotope production companies looking to build facilities in the U.S., Coquí Pharma is the only one using a design and production method already demonstrated throughout the world as safe, efficient and reliable,” stated Carmen Bigles, CEO of Coquí.  Coquí Pharma recently announced their plans to construct the medical isotope production facility at the Sid Martin Biotechnology Incubator in Progress Corporate Park, Alachua, Florida.

The facility will be producing Molybdenum-99, the parent isotope of Technetium-99, the isotope used in 80% of nuclear medicine procedures. Once operational, Coquí Pharma will be capable of supplying a large portion of the U.S. market and, ultimately, the international.

International production sources tend to be older and unreliable, which can delay delivery of potentially life-saving medical diagnostics and treatments to patients.  International facilities also tend to use highly enriched uranium, which can raise proliferation concerns. Coquí has selected INVAP, an internationally recognized Argentinian firm to design and construct the proposed facility. 

INVAP has designed and constructed a number of similar facilities around the world, including the OPAL research reactor in Australia, the RA-3 in Argentina, and other facilities that are successfully producing Mo-99 with low enriched uranium.

For more information: www.coquipharma.com

Related Content

News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...